What is the significance of the two-month time period in patent disclosures?

What is the significance of the two-month time period in patent disclosures? The two-month time period is significant in patent disclosures for the following reasons: Timely disclosure: It encourages prompt submission of information to the USPTO. Avoiding late fees: Submitting within two months can help avoid additional fees for late information disclosure statements. Demonstrating diligence:…

Read More

How does the ‘teaching, suggestion, or motivation’ (TSM) test apply in obviousness determinations?

How does the ‘teaching, suggestion, or motivation’ (TSM) test apply in obviousness determinations? The ‘teaching, suggestion, or motivation’ (TSM) test is an important concept in determining obviousness in patent examination. According to MPEP 2143, while the TSM test is not the sole test for obviousness, it remains a valid approach: “The Supreme Court in KSR…

Read More

What triggers intervening rights in inter partes reexamination?

Intervening rights in inter partes reexamination are triggered when a patent’s claims are amended or new claims are added during the reexamination process. The MPEP 2693 states: “Any proposed amended or new claim determined to be patentable and incorporated into a patent following an inter partes reexamination proceeding shall have the same effect as that…

Read More

What triggers an order for inter partes reexamination?

An order for inter partes reexamination is triggered when the Director finds that a substantial new question of patentability (SNQ) affecting a claim of a patent is raised, or that there is a reasonable likelihood that the requester would prevail (RLP) with respect to at least one of the claims challenged in the request. As…

Read More

How do treatment or prophylaxis limitations relate to other meaningful limitations?

Treatment or prophylaxis limitations are a specific type of meaningful limitation that can render a claim patent-eligible. These limitations are particularly relevant in medical and biotechnology fields. MPEP 2106.05(e) notes: “With respect to treatment or prophylaxis limitations, such as the immunization step in Classen, examiners should note that the other meaningful limitations consideration overlaps with…

Read More

What statement must be included in the transmittal letter for sequence listing submissions on compact disc?

When submitting a sequence listing on compact disc, a specific statement must be included in the transmittal letter. According to MPEP 2422.03: “A statement that the content of the compact disc is duplicative of the written sequence listing, if such a written sequence listing is filed with the application, must be included in the transmittal…

Read More

What are the requirements for submitting a translated “Sequence Listing XML”?

When submitting a translated “Sequence Listing XML”, the following requirements apply: The translation must comply with 37 CFR 1.831 through 1.834. The translated “Sequence Listing XML” should contain English versions of any previously non-English language-dependent free text elements. Updated values for attributes in the root element (37 CFR 1.833(b)(2)(iii)) or elements of the general information…

Read More

How do transitional phrases affect the interpretation of Markush groups in patent claims?

How do transitional phrases affect the interpretation of Markush groups in patent claims? Transitional phrases can significantly impact the interpretation of Markush groups in patent claims: “Consisting of” with Markush groups: Limits the claim to only the listed members of the Markush group. “Comprising” or “including” with Markush groups: Generally interpreted as open-ended, allowing for…

Read More